Hypercalcemia

Hypercalcemia is a metabolic disorder characterized by an abnormally elevated concentration of total or ionized calcium in the blood. In veterinary medicine, hypercalcemia is a clinically significant electrolyte abnormality that can arise from a wide array of underlying diseases, ranging from benign physiologic variations to life-threatening malignancies. The normal reference range for total serum calcium in dogs and cats is typically 8.5–11.5 mg/dL (2.1–2.9 mmol/L), but ionized calcium (iCa) is the physiologically active fraction and should ideally be measured for accurate assessment. Hypercalcemia is classified as mild (11.5–13 mg/dL), moderate (13–15 mg/dL), or severe (>15 mg/dL) in dogs, with similar thresholds in cats. The condition can be acute or chronic, and its clinical manifestations depend on the magnitude, rate of onset, and duration of the calcium elevation. Chronic hypercalcemia often leads to soft tissue mineralization, nephrocalcinosis, and progressive renal failure, while acute severe hypercalcemia can cause cardiac arrhythmias, neurologic signs, and death. The underlying pathophysiologic mechanisms involve either increased intestinal absorption, increased bone resorption, or decreased renal excretion of calcium, often driven by parathyroid hormone (PTH), parathyroid hormone-related protein (PTHrP), calcitriol, or other humoral factors.

The etiologies of hypercalcemia in dogs and cats are numerous and can be categorized into neoplastic, endocrine, renal, toxic, granulomatous, and idiopathic causes. The most common cause in dogs is malignancy, particularly lymphoma, apocrine gland adenocarcinoma of the anal sac, and multiple myeloma. These tumors secrete parathyroid hormone-related protein (PTHrP), which mimics PTH action, leading to increased bone resorption and decreased renal calcium excretion. Other neoplasms associated with hypercalcemia include thymoma, osteosarcoma, mammary carcinoma, and pulmonary carcinoma. In cats, hypercalcemia is frequently idiopathic, but malignancy (lymphoma, squamous cell carcinoma), chronic kidney disease (CKD), and primary hyperparathyroidism are also important causes. Primary hyperparathyroidism, caused by a functional adenoma or hyperplasia of the parathyroid glands, results in excessive PTH secretion and is a common endocrine cause in both species. Hypercalcemia can also arise from vitamin D toxicosis (e.g., ingestion of cholecalciferol rodenticides, calcipotriene creams, or certain plants like Cestrum diurnum), granulomatous diseases (e.g., systemic mycoses such as blastomycosis, histoplasmosis, or tuberculosis) due to unregulated extrarenal production of calcitriol by activated macrophages, and chronic renal failure, where secondary hyperparathyroidism and altered calcium-phosphate balance contribute. Less common causes include hypoadrenocorticism (Addison's disease), hyperthyroidism (in cats), severe osteomyelitis, hypervitaminosis A, and certain medications such as thiazide diuretics, calcium-containing antacids, and lithium. In young animals, congenital or developmental abnormalities such as primary hyperparathyroidism or hereditary hypercalcemia have been reported. Additionally, laboratory artifacts (e.g., lipemia, hemolysis) can cause spurious hypercalcemia, emphasizing the need for ionized calcium measurement.

Hypercalcemia occurs in both dogs and cats, with varying prevalence depending on the underlying cause. In dogs, malignancy-associated hypercalcemia is the most common, accounting for approximately 50-60% of cases, with lymphoma being the most frequent neoplasm, particularly in certain breeds such as Golden Retrievers, Labrador Retrievers, and Boxers. Apocrine gland adenocarcinoma of the anal sac is another notable cause, with a higher incidence in female dogs and breeds like Spaniels and German Shepherds. Primary hyperparathyroidism is more common in middle-aged to older dogs (mean age 10-12 years), with a slight female predisposition, and is seen in breeds like Keeshonden, Siberian Huskies, and mixed breeds. In cats, idiopathic hypercalcemia is the most common diagnosis, often occurring in middle-aged to older cats (mean age 8-10 years), with no clear breed or sex predilection, though Siamese and Domestic Shorthair cats may be overrepresented. Chronic kidney disease (CKD) is a frequent cause of hypercalcemia in older cats, particularly those with IRIS Stage 3 or 4 disease. Hypercalcemia due to vitamin D toxicosis is more common in young animals due to accidental ingestion of rodenticides, with a seasonal peak in spring and fall when rodenticide use is high. Granulomatous diseases are more prevalent in endemic areas for systemic mycoses, such as the Mississippi River Valley for blastomycosis in the United States. Overall, hypercalcemia is a relatively common electrolyte disorder in small animal practice, with a reported prevalence of approximately 1-2% in dogs and 0.5-1% in cats, but it is often an incidental finding on routine biochemistry panels.

The pathophysiology of hypercalcemia involves disruption of the normal calcium-regulating hormones—parathyroid hormone (PTH), calcitriol (1,25-dihydroxyvitamin D), and calcitonin—which maintain extracellular calcium within a narrow range through actions on bone, kidney, and intestine. In malignancy-associated hypercalcemia, tumor cells secrete PTHrP, which binds to PTH receptors in bone and kidney, stimulating osteoclastic bone resorption and increasing renal tubular calcium reabsorption while enhancing phosphate excretion, leading to hypercalcemia and hypophosphatemia. In primary hyperparathyroidism, excessive PTH secretion from a parathyroid adenoma or hyperplasia directly increases bone resorption, renal calcium reabsorption, and calcitriol synthesis, resulting in hypercalcemia and hypophosphatemia. Vitamin D toxicosis causes hypercalcemia by increasing intestinal calcium absorption and bone resorption, with elevated calcitriol levels. Granulomatous diseases lead to unregulated extrarenal production of calcitriol by activated macrophages, which increases intestinal calcium absorption. In chronic kidney disease, hypercalcemia may result from secondary hyperparathyroidism, decreased renal excretion of calcium, and altered vitamin D metabolism, often with concurrent hyperphosphatemia. Hypercalcemia itself has direct pathophysiologic effects on multiple organ systems. In the kidney, hypercalcemia impairs renal concentrating ability (nephrogenic diabetes insipidus), leading to polyuria and polydipsia, and can cause nephrocalcinosis, interstitial nephritis, and progressive renal failure. In the cardiovascular system, hypercalcemia shortens the QT interval, increases myocardial contractility, and can cause arrhythmias, hypertension, and vascular calcification. In the nervous system, hypercalcemia alters neuronal excitability, leading to depression, weakness, and in severe cases, seizures or coma. Gastrointestinal effects include decreased smooth muscle contractility, resulting in anorexia, vomiting, and constipation. Chronic hypercalcemia also promotes soft tissue mineralization, particularly in the kidneys, stomach, lungs, and blood vessels, exacerbating organ dysfunction.

Predisposing factors for hypercalcemia include age, breed, sex, and environmental exposures. In dogs, older animals (≥7 years) are at higher risk for malignancy-associated hypercalcemia, particularly lymphoma and anal sac adenocarcinoma. Certain breeds, such as Golden Retrievers, Labrador Retrievers, and Boxers, have a higher incidence of lymphoma, while Keeshonden and Siberian Huskies are predisposed to primary hyperparathyroidism. Female dogs may be at increased risk for anal sac adenocarcinoma. In cats, middle-aged to older cats are more commonly affected by idiopathic hypercalcemia and CKD, with no strong breed predilection, though Siamese cats may be overrepresented. Environmental factors include access to rodenticides containing cholecalciferol (vitamin D3), which is a common cause of toxicosis in dogs and cats, especially in rural or suburban areas. Ingestion of certain plants (e.g., Cestrum diurnum, Solanum malacoxylon) or excessive dietary vitamin D supplementation can also predispose to hypercalcemia. Concurrent diseases such as chronic kidney disease, hyperthyroidism, or hypoadrenocorticism can increase the risk. Medications that can precipitate hypercalcemia include thiazide diuretics, calcium-containing antacids, and vitamin D analogs (e.g., calcitriol, calcipotriene). Immunosuppression or immunodeficiency may predispose to granulomatous infections (e.g., systemic mycoses) that cause hypercalcemia. Additionally, iatrogenic factors such as over-supplementation of calcium or vitamin D in pets on renal diets or with hypocalcemia can lead to hypercalcemia.

Clinical signs of hypercalcemia vary depending on the severity and chronicity. In mild hypercalcemia (total calcium <12 mg/dL), animals may be asymptomatic or show subtle signs such as mild polyuria and polydipsia. As calcium levels increase, more pronounced signs emerge. Acute hypercalcemia (total calcium >14 mg/dL) often presents with gastrointestinal signs including anorexia, vomiting, constipation, and abdominal pain. Neuromuscular signs include lethargy, depression, muscle weakness, tremors, and in severe cases, seizures or coma. Cardiovascular signs may include bradycardia, arrhythmias, and hypertension. Renal signs are prominent, with polyuria and polydipsia due to impaired renal concentrating ability, and progression to acute kidney injury or chronic kidney disease. In chronic hypercalcemia, signs may be insidious, with weight loss, poor coat condition, and progressive renal failure. Specific underlying causes may have additional signs: lymphoma may present with peripheral lymphadenopathy, hepatosplenomegaly, or mediastinal mass; anal sac adenocarcinoma may cause perianal mass or tenesmus; primary hyperparathyroidism may be associated with urinary calculi (calcium oxalate) and lower urinary tract signs; vitamin D toxicosis may cause severe gastrointestinal signs and renal failure; granulomatous diseases may present with respiratory signs, skin lesions, or ocular involvement. In cats, idiopathic hypercalcemia often presents with vague signs such as lethargy, decreased appetite, and constipation, and may be an incidental finding. Physical examination may reveal dehydration, poor body condition, bradycardia, or arrhythmias, and palpation may reveal abdominal masses or organomegaly.

Differential diagnoses for hypercalcemia include: 1) Malignancy-associated hypercalcemia (lymphoma, anal sac adenocarcinoma, multiple myeloma, thymoma, other carcinomas) – distinguished by presence of tumor, elevated PTHrP, and often hypophosphatemia; 2) Primary hyperparathyroidism – characterized by elevated PTH with normal or low ionized calcium, and often hypophosphatemia; 3) Chronic kidney disease – typically with elevated creatinine, BUN, hyperphosphatemia, and non-regenerative anemia; 4) Vitamin D toxicosis – history of exposure, elevated calcitriol or 25-hydroxyvitamin D, and hyperphosphatemia; 5) Granulomatous disease (e.g., blastomycosis, histoplasmosis) – evidence of fungal infection on cytology or serology, elevated calcitriol; 6) Hypoadrenocorticism – hyperkalemia, hyponatremia, and cortisol response to ACTH stimulation; 7) Hyperthyroidism (cats) – elevated T4, weight loss, and tachycardia; 8) Idiopathic hypercalcemia (cats) – diagnosis of exclusion, normal PTH, PTHrP, and calcitriol; 9) Skeletal lesions (osteomyelitis, metastatic bone tumors) – radiographic evidence of bone lysis; 10) Laboratory error – repeat testing with ionized calcium to rule out artifact. Each differential is ruled in or out based on specific diagnostic tests: PTH, PTHrP, calcitriol, 25-hydroxyvitamin D, imaging (radiography, ultrasound, CT), histopathology, and response to therapy.

The diagnostic approach to hypercalcemia should be systematic. Step 1: Confirm hypercalcemia by repeating total calcium and measuring ionized calcium (iCa) to rule out laboratory artifact. Step 2: Perform a thorough history and physical examination, including palpation of lymph nodes, thyroid/parathyroid region, and rectal examination for anal sac masses. Step 3: Run a complete blood count (CBC), serum biochemistry profile (including BUN, creatinine, phosphorus, total protein, albumin, globulins, and electrolytes), and urinalysis. Step 4: Evaluate for common causes: If lymphoma is suspected, perform thoracic radiographs (for mediastinal mass), abdominal ultrasound (for organomegaly or masses), and fine-needle aspirates of enlarged lymph nodes or masses. If anal sac adenocarcinoma is suspected, perform rectal palpation and ultrasound of the anal sacs. Step 5: Measure serum PTH and PTHrP levels. Elevated PTH with normal or low ionized calcium suggests primary hyperparathyroidism; elevated PTHrP suggests malignancy; low PTH and PTHrP may indicate vitamin D toxicosis, granulomatous disease, or CKD. Step 6: Measure serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D (calcitriol) if vitamin D toxicosis or granulomatous disease is suspected. Step 7: If CKD is present, stage according to IRIS guidelines and assess for secondary hyperparathyroidism. Step 8: If no cause is found, consider advanced imaging (CT, MRI) to identify occult neoplasia or granulomas. Step 9: In cats with no identifiable cause, diagnose idiopathic hypercalcemia after excluding all other causes. Step 10: In refractory cases, consider bone marrow aspiration or biopsy for multiple myeloma or other hematologic malignancies.

Laboratory findings in hypercalcemia vary with the underlying cause. Complete blood count (CBC) may be normal or show anemia of chronic disease, leukocytosis, or lymphopenia. Serum biochemistry typically reveals elevated total calcium (>11.5 mg/dL) and often decreased phosphorus (hypophosphatemia) in primary hyperparathyroidism and malignancy-associated hypercalcemia, but hyperphosphatemia may be present in vitamin D toxicosis, CKD, or granulomatous disease. Blood urea nitrogen (BUN) and creatinine may be elevated due to renal dysfunction. Total protein and albumin may be low in chronic disease or multiple myeloma (with globulin elevation). Electrolyte abnormalities may include hyperkalemia and hyponatremia in hypoadrenocorticism. Urinalysis may show low urine specific gravity (isosthenuria) due to impaired concentrating ability, and may reveal calcium oxalate crystals or hematuria. Blood gas analysis may show metabolic acidosis or alkalosis depending on concurrent disease. Specific biomarkers: Parathyroid hormone (PTH) is elevated in primary hyperparathyroidism and secondary to CKD, but low in malignancy-associated hypercalcemia. Parathyroid hormone-related protein (PTHrP) is elevated in malignancy-associated hypercalcemia. Calcitriol (1,25-dihydroxyvitamin D) is elevated in granulomatous disease and vitamin D toxicosis, while 25-hydroxyvitamin D is elevated in vitamin D toxicosis. Other biomarkers such as SDMA (symmetric dimethylarginine) may be elevated in early renal dysfunction. In multiple myeloma, serum protein electrophoresis shows a monoclonal gammopathy, and urine may contain Bence-Jones proteins. In lymphoma, lactate dehydrogenase (LDH) may be elevated. In granulomatous diseases, serology (e.g., agar gel immunodiffusion for blastomycosis) or antigen testing (e.g., Histoplasma antigen) may be positive.

Imaging plays a crucial role in identifying the underlying cause of hypercalcemia. Thoracic radiographs may reveal a mediastinal mass (thymoma, lymphoma), pulmonary nodules (metastatic disease, granulomas), or sternal lymphadenopathy. Abdominal radiographs may show organomegaly, masses, or urinary calculi (calcium oxalate). Ultrasonography of the abdomen is useful for evaluating the liver, spleen, kidneys, adrenal glands, and lymph nodes, and can guide fine-needle aspiration of masses. In suspected primary hyperparathyroidism, cervical ultrasound may identify a parathyroid adenoma or hyperplasia, though sensitivity is variable. Computed tomography (CT) is more sensitive for detecting small masses, particularly in the thorax or abdomen, and can be used for staging of neoplasia. Magnetic resonance imaging (MRI) may be indicated for suspected brain or spinal lesions, though rare. Echocardiography may be performed if cardiac signs are present, but is not routinely indicated. In cases of suspected skeletal involvement (e.g., multiple myeloma, metastatic bone tumors), radiographs of the axial and appendicular skeleton may show lytic lesions. In granulomatous disease, thoracic radiographs may show interstitial or alveolar patterns, and abdominal ultrasound may reveal hepatosplenomegaly or lymphadenopathy. In chronic kidney disease, renal ultrasound may show small, irregular kidneys with increased echogenicity. In vitamin D toxicosis, radiographs may show soft tissue mineralization, particularly in the kidneys, stomach, and blood vessels.

Cytologic and histopathologic evaluation is essential for definitive diagnosis of the underlying cause of hypercalcemia. Fine-needle aspiration (FNA) of enlarged lymph nodes, masses, or organs (e.g., liver, spleen) can diagnose lymphoma (large, atypical lymphocytes), anal sac adenocarcinoma (clusters of epithelial cells with variable atypia), or multiple myeloma (plasma cells). FNA of a parathyroid mass may reveal sheets of chief cells, but is rarely performed due to risk. Histopathology of excised masses (e.g., lymph node biopsy, anal sac adenocarcinoma resection) provides a definitive diagnosis and grading. In granulomatous diseases, cytology or histopathology may reveal pyogranulomatous inflammation with fungal organisms (e.g., Blastomyces dermatitidis, Histoplasma capsulatum) identified on special stains (GMS, PAS). In primary hyperparathyroidism, histopathology of the parathyroid gland shows adenoma (well-circumscribed, encapsulated) or hyperplasia (multicellular). In chronic kidney disease, renal biopsy may show interstitial fibrosis, tubular atrophy, and mineralization. In vitamin D toxicosis, histopathology may show soft tissue mineralization in multiple organs. In idiopathic hypercalcemia of cats, no specific histopathologic changes are seen, and the diagnosis is one of exclusion. Bone marrow aspiration or biopsy may be indicated if multiple myeloma or other hematologic malignancy is suspected, revealing increased plasma cells or abnormal cell populations.

Treatment of hypercalcemia depends on the severity, underlying cause, and clinical signs. Emergency management is required for severe hypercalcemia (total calcium >15 mg/dL) or symptomatic patients. Initial therapy includes aggressive intravenous fluid therapy with 0.9% sodium chloride (NaCl) at rates of 60-100 mL/kg/day (dogs) or 40-60 mL/kg/day (cats) to promote renal calcium excretion and correct dehydration. Furosemide (1-2 mg/kg IV or PO q8-12h) may be added after rehydration to enhance calciuresis, but should be used cautiously to avoid dehydration and electrolyte imbalances. Corticosteroids (e.g., prednisone 1-2 mg/kg/day PO or dexamethasone 0.1-0.2 mg/kg IV) are effective in malignancy-associated hypercalcemia and granulomatous disease by reducing PTHrP production and calcitriol synthesis, but should be withheld until a definitive diagnosis is made, as they may interfere with diagnostic testing (e.g., lymphoma). Calcitonin (4-6 IU/kg SC or IM q8-12h) can be used for rapid reduction of calcium, but its effect is transient. Bisphosphonates, such as pamidronate (1-2 mg/kg IV over 2-4 hours) or alendronate (10-20 mg/dog PO q24h), inhibit osteoclastic bone resorption and are effective for malignancy-associated hypercalcemia and vitamin D toxicosis. For primary hyperparathyroidism, surgical removal of the parathyroid adenoma is the treatment of choice. For CKD-associated hypercalcemia, management includes dietary phosphate restriction, calcitriol (if indicated for secondary hyperparathyroidism), and treatment of renal failure. For vitamin D toxicosis, treatment includes decontamination (induction of vomiting if recent ingestion), activated charcoal, and supportive care with fluids, furosemide, corticosteroids, and bisphosphonates. For granulomatous disease, antifungal therapy (e.g., itraconazole 5-10 mg/kg PO q12-24h) is indicated. For idiopathic hypercalcemia in cats, treatment may include dietary modification (low-calcium diet), prednisolone (1-2 mg/kg/day PO), or alendronate (10 mg/cat PO weekly). In all cases, monitoring of serum calcium, renal function, and electrolytes is essential.

The prognosis for hypercalcemia depends on the underlying cause and the severity at presentation. In malignancy-associated hypercalcemia, the prognosis is generally poor, with median survival times of 3-6 months for lymphoma and 6-12 months for anal sac adenocarcinoma, depending on stage and response to chemotherapy. Primary hyperparathyroidism has a good to excellent prognosis after surgical removal of the adenoma, with resolution of hypercalcemia in most cases, though transient hypocalcemia may occur postoperatively. Vitamin D toxicosis has a guarded prognosis, with survival rates of 50-70% if treated aggressively, but severe renal failure may develop. Granulomatous diseases have a fair to good prognosis with appropriate antifungal therapy, though relapse is possible. Chronic kidney disease-associated hypercalcemia has a guarded prognosis, as it indicates advanced renal dysfunction. Idiopathic hypercalcemia in cats has a variable prognosis; many cats respond to dietary or medical management, but some may develop progressive renal disease. Negative prognostic indicators include severe hypercalcemia (>15 mg/dL), azotemia at presentation, and lack of response to initial therapy. Positive prognostic indicators include early diagnosis, mild hypercalcemia, and identification of a treatable cause.

Follow-up monitoring is crucial for patients with hypercalcemia. Initially, serum calcium, ionized calcium, and renal parameters (BUN, creatinine, electrolytes) should be rechecked daily during hospitalization until calcium levels normalize. After discharge, recheck serum calcium and renal function weekly for the first month, then monthly for 3-6 months, and then every 3-6 months long-term. For patients on bisphosphonates, monitor for hypocalcemia and renal function. For those on corticosteroids, monitor for side effects (e.g., polyuria, polydipsia, gastrointestinal ulceration). For patients with primary hyperparathyroidism, postoperative monitoring of calcium is essential, as hypocalcemia can occur due to suppression of normal parathyroid tissue; calcium and PTH should be rechecked at 1, 2, and 4 weeks post-surgery, then every 3-6 months. For malignancy-associated hypercalcemia, monitor tumor response and calcium levels during chemotherapy. For CKD, follow IRIS guidelines for staging and monitoring. For idiopathic hypercalcemia in cats, recheck calcium every 3-6 months and adjust treatment as needed. Imaging (e.g., ultrasound, radiographs) should be repeated as clinically indicated to monitor tumor progression or recurrence.

Pearls: 1) Always measure ionized calcium to confirm true hypercalcemia, as total calcium can be affected by albumin and protein levels. 2) In dogs, malignancy is the most common cause, so a thorough search for neoplasia is essential. 3) In cats, idiopathic hypercalcemia is common, but rule out CKD and malignancy first. 4) PTH and PTHrP measurements are key to differentiating causes. 5) Aggressive fluid therapy is the cornerstone of emergency management. 6) Corticosteroids should be used cautiously before a definitive diagnosis, as they can lyse lymphoma cells and obscure diagnosis. 7) Bisphosphonates are effective for severe hypercalcemia but take 24-48 hours to work. Pitfalls: 1) Failing to correct for hypoalbuminemia, leading to false hypercalcemia. 2) Using furosemide before rehydration, causing dehydration and worsening hypercalcemia. 3) Administering corticosteroids without a diagnosis, potentially masking lymphoma. 4) Overlooking anal sac adenocarcinoma in dogs with hypercalcemia. 5) Not monitoring for hypocalcemia after treatment of primary hyperparathyroidism. 6) Assuming hypercalcemia is idiopathic in cats without ruling out occult neoplasia or CKD. 7) Neglecting to measure ionized calcium in cases with borderline total calcium.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for hypercalcemia: 1) Fluid therapy: 0.9% NaCl IV at 60-100 mL/kg/day (dogs) or 40-60 mL/kg/day (cats) for rehydration and calciuresis. 2) Furosemide: 1-2 mg/kg IV or PO q8-12h, after rehydration, to promote calcium excretion. 3) Prednisone: 1-2 mg/kg/day PO (dogs) or 1-2 mg/kg/day PO (cats) for malignancy-associated hypercalcemia or granulomatous disease; use with caution. 4) Dexamethasone: 0.1-0.2 mg/kg IV q24h for acute management. 5) Calcitonin (salmon calcitonin): 4-6 IU/kg SC or IM q8-12h, for rapid reduction of calcium; monitor for hypocalcemia. 6) Pamidronate: 1-2 mg/kg IV diluted in 0.9% NaCl, infused over 2-4 hours, once; may repeat in 1-2 weeks if needed. 7) Alendronate: 10-20 mg/dog PO q24h (dogs) or 10 mg/cat PO weekly (cats), for chronic management. 8) For primary hyperparathyroidism: surgical excision; if surgery not possible, consider calcimimetics (e.g., cinacalcet) at 0.5-2 mg/kg PO q24h, though not widely used in veterinary medicine. 9) For vitamin D toxicosis: decontamination with activated charcoal (1-2 g/kg PO) if recent ingestion; furosemide, prednisone, and pamidronate as above. 10) For granulomatous disease: itraconazole 5-10 mg/kg PO q12-24h (dogs) or 5-10 mg/kg PO q12-24h (cats) for systemic mycoses. 11) For CKD-associated hypercalcemia: dietary phosphate restriction, calcitriol (2.5-6.5 ng/kg/day PO) if indicated for secondary hyperparathyroidism, and management of renal failure. 12) For idiopathic hypercalcemia in cats: dietary modification (low-calcium diet), prednisolone 1-2 mg/kg/day PO, or alendronate 10 mg/cat PO weekly. Always adjust dosages for renal or hepatic impairment and monitor for drug interactions.

Evidence-based literature on hypercalcemia in dogs and cats includes several key studies and consensus guidelines. A landmark study by Elliott et al. (1991) identified malignancy as the most common cause of hypercalcemia in dogs, with lymphoma and anal sac adenocarcinoma being the most frequent neoplasms. Another study by Vasilopulos et al. (2005) evaluated the diagnostic utility of PTH and PTHrP in differentiating causes of hypercalcemia, finding that PTHrP was elevated in 80% of malignancy-associated cases. In cats, a study by Savary et al. (2000) reported that idiopathic hypercalcemia is the most common diagnosis, and a more recent study by McClain et al. (2018) found that CKD is a significant cause in older cats. The ACVIM consensus statement on hypercalcemia (2016) provides guidelines for diagnosis and management, emphasizing the importance of ionized calcium measurement and a systematic diagnostic approach. Regarding treatment, a study by Hostutler et al. (2005) demonstrated the efficacy of pamidronate in reducing calcium levels in dogs with malignancy-associated hypercalcemia. Another study by Chew et al. (2006) evaluated the use of alendronate in cats with idiopathic hypercalcemia, showing improvement in clinical signs and calcium levels. For primary hyperparathyroidism, a study by Feldman et al. (2005) reported successful surgical outcomes in 95% of dogs. In vitamin D toxicosis, a retrospective study by Peterson et al. (2007) showed that aggressive treatment with fluids, furosemide, and bisphosphonates improved survival. Overall, the literature supports a thorough diagnostic workup and targeted therapy based on the underlying cause.